by Gemma Escarré,
Vytrus Biotech, a CataloniaBio & HealthTech member company, has successfully closed the €1-million round of funding it began in the fourth quarter of 2017.
This injection of funds will allow the company to continue its expansion strategy, which includes going public on the Spanish Alternative Stock Exchange (Mercado Alternativo Bursátil - MAB) in 2019. After this increase, the company now has approximately 200 shareholders.
Vytrus Biotech was created in 2009 in Terrassa by entrepreneurs Albert Jané and Óscar Expósito as a spin-off of the University of Barcelona Faculty of Pharmacy. The company’s business is based on plant biotechnology and stem cells. In 2017, Vytrus doubled its revenue and posted sales of €650,000. In 2018, the company expects to see revenue over €1 million.
Photo: Company founders, Albert Janéand Óscar Expósito - © Vytrus Biotech